EP Patent

EP2563775A1 — Pyrazolyl quinazoline kinase inhibitors

Assigned to Astex Therapeutics Ltd · Expires 2013-03-06 · 13y expired

What this patent protects

The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

USPTO Abstract

The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

Drugs covered by this patent

Patent Metadata

Patent number
EP2563775A1
Jurisdiction
EP
Classification
—
Expires
2013-03-06
Drug substance claim
No
Drug product claim
No
Assignee
Astex Therapeutics Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.